Acer Therapeutics Inc.
Index- P/E- EPS (ttm)-1.44 Insider Own19.50% Shs Outstand16.09M Perf Week1.13%
Market Cap12.74M Forward P/E- EPS next Y-0.67 Insider Trans60.08% Shs Float13.36M Perf Month-63.00%
Income-21.30M PEG- EPS next Q-0.37 Inst Own26.10% Short Float / Ratio2.53% / 0.75 Perf Quarter-70.83%
Sales0.40M P/S31.86 EPS this Y47.60% Inst Trans0.99% Short Interest0.34M Perf Half Y-45.82%
Book/sh-0.76 P/B- EPS next Y55.40% ROA-80.10% Target Price8.50 Perf Year-73.84%
Cash/sh0.38 P/C1.99 EPS next 5Y- ROE259.30% 52W Range0.65 - 4.56 Perf YTD-69.78%
Dividend- P/FCF- EPS past 5Y38.00% ROI902.80% 52W High-83.37% Beta0.72
Dividend %- Quick Ratio0.40 Sales past 5Y-15.40% Gross Margin- 52W Low16.69% ATR0.14
Employees35 Current Ratio0.40 Sales Q/Q- Oper. Margin- RSI (14)22.88 Volatility7.72% 12.83%
OptionableYes Debt/Eq- EPS Q/Q-36.10% Profit Margin- Rel Volume0.35 Prev Close0.75
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume452.59K Price0.76
Recom2.00 SMA20-39.13% SMA50-58.49% SMA200-55.37% Volume157,707 Change1.13%
Jun-26-19Reiterated H.C. Wainwright Buy $55 → $10
Jun-25-19Downgrade William Blair Outperform → Mkt Perform
Jun-25-19Downgrade Raymond James Outperform → Mkt Perform
May-23-19Initiated Wedbush Outperform
Feb-15-19Resumed Raymond James Outperform $40
Dec-20-18Initiated Needham Buy $48
Feb-26-18Initiated ROTH Capital Buy
Dec-20-17Initiated H.C. Wainwright Buy $50
Mar-27-23 04:01PM
Mar-22-23 08:30AM
Mar-20-23 12:01PM
Mar-17-23 01:34PM
08:30AM Loading…
Mar-15-23 08:30AM
Mar-10-23 05:50PM
Feb-23-23 05:50PM
Feb-22-23 06:00PM
Feb-13-23 08:30AM
Feb-10-23 05:50PM
Feb-01-23 05:50PM
Jan-31-23 08:00AM
07:05AM Loading…
Jan-27-23 07:05AM
Jan-25-23 06:00PM
Jan-19-23 06:00PM
Jan-18-23 08:49AM
Jan-16-23 09:40AM
Jan-10-23 06:00PM
Jan-09-23 08:30AM
Jan-05-23 08:30AM
Dec-29-22 09:40AM
Dec-28-22 12:00PM
Dec-27-22 08:30AM
02:47PM Loading…
Dec-23-22 02:47PM
Dec-13-22 09:40AM
Dec-08-22 09:35PM
Dec-04-22 07:17AM
Nov-30-22 08:30AM
Nov-17-22 05:37AM
Nov-14-22 05:08PM
Oct-26-22 08:30AM
Oct-18-22 04:05PM
Oct-06-22 08:30AM
Oct-05-22 01:44PM
Oct-03-22 08:30AM
Sep-30-22 11:47AM
Sep-29-22 11:42AM
Sep-15-22 01:28PM
Sep-13-22 11:58AM
Aug-23-22 08:30AM
Aug-15-22 04:00PM
Aug-12-22 08:30AM
Jul-28-22 08:33AM
Jul-18-22 08:30AM
Jul-15-22 06:15AM
Jul-08-22 08:30AM
Jun-28-22 06:16AM
Jun-27-22 08:30AM
Jun-23-22 08:14AM
Jun-22-22 09:43AM
Jun-21-22 01:12PM
Jun-15-22 08:49AM
Jun-09-22 05:18AM
Jun-07-22 08:30AM
Jun-06-22 06:05AM
May-16-22 06:55PM
May-12-22 08:15AM
May-09-22 08:30AM
May-06-22 08:30AM
May-05-22 08:30AM
Apr-12-22 08:30AM
Apr-11-22 03:48PM
Apr-04-22 08:30AM
Mar-31-22 08:30AM
Mar-30-22 08:30AM
Mar-28-22 07:00AM
Mar-07-22 06:15AM
Mar-02-22 05:18PM
Feb-22-22 08:30AM
Feb-08-22 02:44PM
Feb-01-22 08:30AM
Jan-27-22 08:30AM
Jan-13-22 09:40AM
Jan-07-22 04:29AM
Dec-22-21 08:30AM
Dec-09-21 08:30AM
Nov-22-21 03:43AM
Nov-19-21 05:00PM
Oct-26-21 08:30AM
Oct-09-21 08:09AM
Oct-07-21 10:58AM
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was incorporated in 1991 and is headquartered in Newton, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schelling ChrisPresident & CEONov 29Buy1.22819,6721,000,0002,712,529Dec 01 04:02 PM
ASELAGE STEVEDirectorNov 29Buy1.22409,836500,000483,741Dec 01 04:01 PM